Jazz Pharmaceuticals plc (JAZZ) Key Metrics
JAZZ valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $13.65B
- Enterprise value
- $17.47B
- P/E (TTM)
- 14.4 10-yr median 17.0
- Forward P/E
- 10.9
- PEG ratio
- 0.96
- Price / sales
- 3.0 10-yr median 3.3
- Price / book
- 3.3 10-yr median 2.7
- EV / EBITDA
- 11.0 10-yr median 9.7
- Dividend yield
- —
- Beta
- 0.37
JAZZ key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsJAZZ valuation Price multiples at each fiscal year-end price.
JAZZ returns How much profit the business earns on the capital it uses.
JAZZ per-share figures Results divided by the shares outstanding at year-end.
JAZZ financial health Debt, liquidity and how easily interest is covered.
JAZZ efficiency & capital use Working capital cycle and where the cash goes.
JAZZ valuation history
JAZZ returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
JAZZ debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
JAZZ cash returned to shareholders
JAZZ price vs earnings per share
JAZZ key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $10.37B | $8.13B | $8.86B | $9.96B | $7.61B | $9.33B | $8.59B | $7.59B | $8.26B | $6.75B |
| Enterprise value | $13.35B | $11.30B | $13.03B | $14.89B | $13.17B | $9.44B | $9.28B | $8.36B | $9.24B | $8.35B |
| P/E ratio | — | 14.5 | 21.4 | — | — | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 |
| Price / sales | 2.4 | 2.0 | 2.3 | 2.7 | 2.5 | 3.9 | 4.0 | 4.0 | 5.1 | 4.5 |
| Price / book | 2.4 | 2.0 | 2.4 | 3.2 | 1.9 | 2.5 | 2.8 | 2.8 | 3.0 | 3.6 |
| Price / free cash flow | 9.0 | 6.0 | 8.3 | 12.9 | 10.4 | 17.9 | 14.5 | 11.4 | 14.3 | 16.5 |
| Price / operating cash flow | 7.6 | 5.8 | 8.1 | 7.8 | 9.8 | 10.4 | 11.1 | 9.5 | 11.9 | 11.4 |
| EV / sales | 3.1 | 2.8 | 3.4 | 4.1 | 4.3 | 4.0 | 4.3 | 4.4 | 5.7 | 5.6 |
| EV / EBITDA | 50.8 | 7.4 | 9.0 | 10.1 | 12.8 | 9.0 | 9.2 | 9.0 | 11.9 | 11.1 |
| EV / free cash flow | 11.6 | 8.4 | 12.2 | 19.2 | 18.0 | 18.1 | 15.6 | 12.5 | 15.9 | 20.4 |
| Earnings yield | −3.4% | 6.9% | 4.7% | −2.2% | −4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% |
| Free cash flow yield | 11.1% | 16.6% | 12.0% | 7.8% | 9.6% | 5.6% | 6.9% | 8.8% | 7.0% | 6.1% |
| Dividend yield | — | — | — | 1.0% | 1.3% | 1.1% | 0.7% | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 1.2% | 3.8% | 3.0% | 1.0% | 1.8% | 2.6% | 4.2% | 6.9% | 1.2% | 4.1% |
| Share price at fiscal year-end | $170.00 | $123.15 | $123.00 | $159.31 | $127.40 | $165.05 | $149.28 | $123.96 | $134.65 | $109.03 |
| Per share | ||||||||||
| Revenue per share | $69.98 | $61.64 | $53.20 | $58.51 | $51.83 | $41.82 | $37.56 | $30.89 | $26.40 | $24.05 |
| Earnings per share | −$5.84 | $8.49 | $5.76 | −$3.58 | −$5.51 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 |
| Operating cash flow per share | $22.23 | $21.15 | $15.15 | $20.34 | $13.04 | $15.92 | $13.49 | $13.05 | $11.30 | $9.54 |
| Free cash flow per share | $18.79 | $20.42 | $14.82 | $12.37 | $12.28 | $9.21 | $10.32 | $10.90 | $9.44 | $6.61 |
| Cash per share | $40.04 | $45.34 | $22.57 | $14.09 | $9.91 | $37.74 | $18.72 | $13.47 | $9.80 | $6.88 |
| Book value per share | $70.81 | $62.02 | $51.86 | $49.34 | $66.43 | $64.75 | $54.06 | $45.04 | $44.25 | $30.34 |
| Tangible book value per share | −$31.82 | −$36.03 | −$47.65 | −$70.38 | −$84.01 | $8.96 | −$4.34 | −$14.73 | −$19.79 | −$32.79 |
| Dividends per share | — | — | — | $1.57 | $1.67 | $1.76 | $1.00 | — | $0.00 | $0.00 |
| Capex per share | $3.44 | $0.73 | $0.33 | $7.97 | $0.76 | $6.71 | $3.17 | $2.15 | $1.86 | $2.93 |
| Debt per share | $88.94 | $93.36 | $80.37 | $92.94 | $103.07 | $39.80 | $30.78 | $26.08 | $25.78 | $32.80 |
| Shares outstanding | 61.0M | 66.0M | 72.1M | 62.5M | 59.7M | 56.5M | 57.5M | 61.2M | 61.3M | 61.9M |
| Change in shares outstanding | −7.6% | −8.4% | +15.2% | +4.8% | +5.6% | −1.8% | −6.0% | −0.2% | −0.9% | −1.8% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −8.5% | 14.3% | 12.2% | −6.4% | −8.6% | 7.0% | 17.8% | 16.3% | 21.3% | 22.8% |
| Return on invested capital (ROIC) | 2.4% | 9.5% | 7.3% | −0.6% | 2.0% | 8.7% | 14.5% | 14.4% | 14.7% | 16.7% |
| Return on assets (ROA) | −3.0% | 4.8% | 3.7% | −1.9% | −3.5% | 4.0% | 9.7% | 8.7% | 9.8% | 9.7% |
| Return on tangible assets | −6.6% | 10.1% | 9.8% | −6.7% | −9.9% | 7.1% | 24.0% | 28.9% | 40.8% | 44.4% |
| Free cash flow margin | 26.9% | 33.1% | 27.9% | 21.1% | 23.7% | 22.0% | 27.5% | 35.3% | 35.8% | 27.5% |
| Income quality (OCF / net income) | — | 2.49 | 2.63 | — | — | 3.77 | 1.48 | 1.79 | 1.42 | 1.49 |
| Financial health | ||||||||||
| Total debt | $5.42B | $6.16B | $5.79B | $5.81B | $6.15B | $2.25B | $1.77B | $1.60B | $1.58B | $2.03B |
| Cash & short-term investments | $2.44B | $2.99B | $1.63B | $881.5M | $591.4M | $2.13B | $1.08B | $824.6M | $601.0M | $426.0M |
| Net debt | $2.98B | $3.17B | $4.17B | $4.93B | $5.56B | $116.6M | $693.9M | $771.8M | $980.0M | $1.60B |
| Debt / equity | 1.26 | 1.51 | 1.55 | 1.88 | 1.55 | 0.61 | 0.57 | 0.58 | 0.58 | 1.08 |
| Debt / assets | 0.47 | 0.51 | 0.51 | 0.54 | 0.50 | 0.34 | 0.32 | 0.31 | 0.31 | 0.42 |
| Net debt / EBITDA | 11.35 | 2.08 | 2.87 | 3.36 | 5.41 | 0.11 | 0.69 | 0.83 | 1.26 | 2.13 |
| Current ratio | 1.86 | 4.46 | 2.24 | 2.79 | 3.23 | 4.34 | 4.47 | 3.57 | 3.29 | 2.91 |
| Quick ratio | 1.67 | 3.99 | 1.85 | 2.03 | 1.90 | 4.20 | 4.26 | 3.42 | 3.15 | 2.77 |
| Interest coverage | 1.2 | 3.0 | 2.0 | -0.2 | 0.6 | 3.8 | 7.4 | 7.8 | 6.8 | 9.6 |
| Working capital | $1.92B | $3.59B | $1.90B | $1.67B | $1.80B | $2.19B | $1.27B | $888.5M | $674.3M | $490.7M |
| Invested capital | $7.30B | $7.26B | $7.90B | $8.02B | $9.53B | $3.78B | $3.80B | $3.53B | $3.69B | $3.48B |
| Tangible asset value | −$1.94B | −$2.38B | −$3.43B | −$4.40B | −$5.01B | $506.4M | −$250.0M | −$901.5M | −$1.21B | −$2.03B |
| Net current asset value | −$3.17B | −$3.29B | −$4.22B | −$5.14B | −$5.72B | −$36.6M | −$797.6M | −$1.21B | −$1.44B | −$2.17B |
| Graham number | — | $108.82 | $81.95 | — | — | $78.43 | $105.17 | $86.03 | $89.00 | $66.17 |
| Graham net-net per share | −$66.69 | −$62.84 | −$72.19 | −$96.30 | −$113.63 | −$7.05 | −$18.15 | −$22.82 | −$26.42 | −$37.24 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $98.0M | $99.7M | $99.7M | $57.8M | — | $0 | $0 |
| Share buybacks (net) | $125.0M | $311.4M | $269.8M | $54,000 | $35.6M | $146.5M | $301.4M | $523.7M | $98.8M | $278.3M |
| Dividend payout ratio | — | — | — | — | — | 41.8% | 11.0% | — | 0.0% | 0.0% |
| Dividends + buybacks / free cash flow | 10.9% | 23.1% | 25.3% | 12.7% | 18.5% | 47.3% | 60.5% | 78.5% | 17.1% | 68.1% |
| Capex / revenue | 4.9% | 1.2% | 0.6% | 13.6% | 1.5% | 16.0% | 8.4% | 7.0% | 7.0% | 12.2% |
| Capex / operating cash flow | 15.5% | 3.4% | 2.2% | 39.2% | 5.8% | 42.2% | 23.5% | 16.5% | 16.4% | 30.7% |
| Capex / depreciation | 0.30 | 0.07 | 0.04 | 0.79 | 0.08 | 1.36 | 0.49 | 0.61 | 0.69 | 1.60 |
| Stock-based compensation / revenue | 6.8% | 6.1% | 5.9% | 6.1% | 6.1% | 5.1% | 5.1% | 5.4% | 6.6% | 6.6% |
| R&D / revenue | 18.3% | 21.7% | 22.2% | 16.1% | 16.3% | 14.2% | 13.9% | 12.0% | 12.3% | 10.9% |
| SG&A / revenue | 42.4% | 34.0% | 34.7% | 38.7% | 46.9% | 36.1% | 34.1% | 36.1% | 33.6% | 33.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 66.2 | 63.8 | 64.6 | 60.6 | 56.6 | 58.1 | 52.3 | 47.1 | 51.7 | 54.4 |
| Days of inventory on hand | 325.4 | 441.2 | 549.3 | 603.3 | 483.7 | 213.2 | 187.7 | 144.4 | 128.0 | 92.7 |
| Days payables outstanding | 72.5 | 74.0 | 81.1 | 64.5 | 52.7 | 91.3 | 125.7 | 97.6 | 77.5 | 76.6 |
| Cash conversion cycle (days) | 319.1 | 431.0 | 532.9 | 599.4 | 487.6 | 180.1 | 114.3 | 94.0 | 102.2 | 70.5 |
| Receivables turnover | 5.52 | 5.72 | 5.65 | 6.02 | 6.45 | 6.28 | 6.98 | 7.75 | 7.06 | 6.70 |
| Payables turnover | 5.03 | 4.94 | 4.50 | 5.66 | 6.93 | 4.00 | 2.90 | 3.74 | 4.71 | 4.77 |
| Inventory turnover | 1.12 | 0.83 | 0.66 | 0.61 | 0.75 | 1.71 | 1.94 | 2.53 | 2.85 | 3.94 |
| Asset turnover | 0.36 | 0.35 | 0.34 | 0.32 | 0.33 | 0.39 | 0.40 | 0.37 | 0.33 | 0.36 |
| Average receivables | $773.8M | $711.3M | $678.6M | $607.4M | $479.9M | $376.2M | $309.9M | $244.0M | $229.2M | $222.0M |
| Average payables | $100.0M | $90.3M | $96.8M | $95.5M | $63.6M | $37.2M | $44.1M | $32.5M | $23.4M | $22.1M |
| Average inventory | $448.7M | $538.7M | $655.5M | $893.4M | $584.1M | $87.0M | $65.8M | $48.1M | $38.6M | $26.8M |
| Intangibles / total assets | 53.7% | 53.9% | 62.9% | 69.1% | 73.0% | 48.2% | 60.7% | 70.3% | 76.6% | 81.4% |
Computed from JAZZ's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
JAZZ valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 14.4 and the forward P/E is 10.9. Jazz Pharmaceuticals earned a return on equity of −8.5% and a return on invested capital of 2.4% in fiscal 2025. It ended the year with $5.4 billion of debt and $2.4 billion in cash and short-term investments, net debt of $3.0 billion. It returned $125.0 million to shareholders: $0 in dividends and $125.0 million in share buybacks, 11% of free cash flow.
See the JAZZ income statement, the JAZZ chart for price history, or the JAZZ stock overview for the latest quote and news.
JAZZ key metrics FAQ
What is Jazz Pharmaceuticals's P/E ratio?
Jazz Pharmaceuticals's trailing P/E ratio is 14.4 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 10.9. At the end of fiscal 2025 it was —, compared with a 10-year median of 17.0.
What is Jazz Pharmaceuticals's EV/EBITDA?
Jazz Pharmaceuticals's enterprise value was 50.8 times EBITDA at the end of fiscal 2025 (enterprise value $13.3 billion, EBITDA $262.8 million); the current EV/EBITDA is 11.0.
What is Jazz Pharmaceuticals's return on equity?
Jazz Pharmaceuticals's return on equity (ROE) was −8.5% in fiscal 2025: net income of -$356.1 million on average shareholders' equity of $4.2 billion.
What is Jazz Pharmaceuticals's ROIC?
Jazz Pharmaceuticals's return on invested capital was 2.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals had total debt of $5.4 billion at the end of fiscal 2025, a debt-to-equity ratio of 1.26 and $3.0 billion of net debt (11.35 times EBITDA).
Does Jazz Pharmaceuticals buy back its shares?
Yes. Jazz Pharmaceuticals spent $125.0 million on net share repurchases in fiscal 2025 Shares outstanding changed −7.6% over the year, to 61.0M..
What is Jazz Pharmaceuticals's free cash flow yield?
Jazz Pharmaceuticals generated $1.1 billion of free cash flow in fiscal 2025, a free cash flow yield of 11.1% on its market value at year-end ($10.4 billion).
What is Jazz Pharmaceuticals's current ratio?
Jazz Pharmaceuticals's current ratio was 1.86 at the end of fiscal 2025: current assets were 1.86 times current liabilities.